University of Florida Health researchers have developed a mouse model of the most common genetic mutation that causes amyotrophic lateral sclerosis (ALS). The model, which captures the molecular, behavioral, and neurodegenerative features of the disease, could greatly aid in the development of more effective therapeutic agents. The paper detailing the model,…
News
The University of California at San Francisco (UCSF) has announced that a new UCSF Weill Institute for Neurosciences will be established, made possible by $185 million in funding — the largest-ever gift to the university and one of the largest ever made to support the neurosciences in the U.S. —…
Results from the Phase 3 trial of edaravone (MCI-186) in amyotrophic lateral sclerosis (ALS) were presented by Mitsubishi Tanabe Pharma Corporation at the 68th Annual Meeting of the American Academy of Neurology held April 15-21 in Vancouver, British Columbia. The Phase 3 MCI-186-19 clinical study has reportedly met its primary efficacy endpoint of mean change…
The ALS Association and the American Academy of Neurology (AAN) announced the 2016 winners of its Clinical Research Training Fellowship and Clinician-Scientist Development Award in amyotrophic lateral sclerosis (ALS) research. The awards are given annually to young clinicians who propose promising and innovative ALS studies, both to foster their professional development…
Lauren Sciences, LLC, which specializes in medicines for neurodegenerative disorders using its V-Smart drug delivery platform, announced that it has received a second grant from the ALS Association to continue developing LAUR-301, a V-Smart nanomedicine targeting brain areas affected by motor neuron death in amyotrophic lateral sclerosis (ALS). LAUR-301, developed using the V-Smart platform nanotechnology, is…
News
King’s College London ALS Researcher Honored with $50,000 Sheila Essey Award at AAN Annual Meeting
The ALS Association and the American Academy of Neurology (AAN) have chosen Professor Ammar Al-Chalabi of King’s College London to receive the 2016 Sheila Essey Award, honoring his contributions to amyotrophic lateral sclerosis (ALS) research and treatment. Ammar Al-Chalabi Dr. Al-Chalabi will be given the…
ALS Cellucci Fund runner Chris Benyo and his wife, Denise DiMarzo, who has amyotrophic lateral sclerosis (ALS), are competing in this year’s Boston Marathon using a custom wheelchair designed for the race. Illinois residents Benyo and DiMarzo make up two of the six people representing the UMass ALS team in…
Researchers have succeeded in using an imaging technique to record changes and inflammation in the brain of a person with amyotrophic lateral sclerosis (ALS), using a potential biomarker of inflammation. The research, conducted at The Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital, is part of the TRACK ALS project to identify imaging markers of ALS, so…
An after-school study by two teenagers in Canada found that maple syrup protects neurons and halts the development of amyotrophic lateral sclerosis (ALS) in an animal model of the disease. While the study was intended for educational purposes, its discoveries that might be of interest to drug developers. The students, Catherine Aaron and…
News
AB Science Reviews Ongoing Phase 3 Study of Masitinib as ALS Treatment in Conference with Experts
AB Science recently reported positive data from an interim analysis of a Phase 2/3 study of masitinib, its lead compound to treat amyotrophic lateral sclerosis (ALS). The company also held a web conference with leading ALS experts on April 8, followed by a report summarizing the ongoing trial. Masitinib is a…
Recent Posts
- New rare gene variants tied to ALS risk in large international genetic analysis
- ALS patients, caregivers prefer team-based care model, new survey finds
- ALS partnership to give 6 patients expanded access to TRE-515
- Frustration mounts when ALS assistive technology isn’t so helpful
- Trial of experimental ALS therapy pridopidine enrolls first participant